Danske Bank A S Buys Shares of 358,171 Amgen Inc. $AMGN

Danske Bank A S bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 358,171 shares of the medical research company’s stock, valued at approximately $101,076,000. Danske Bank A S owned approximately 0.07% of Amgen as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mizuho Markets Cayman LP grew its holdings in shares of Amgen by 1.0% during the third quarter. Mizuho Markets Cayman LP now owns 490,470 shares of the medical research company’s stock valued at $138,411,000 after buying an additional 4,823 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Amgen by 435.8% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 284 shares of the medical research company’s stock worth $80,000 after acquiring an additional 231 shares in the last quarter. Stance Capital LLC lifted its stake in Amgen by 28.4% in the 3rd quarter. Stance Capital LLC now owns 5,730 shares of the medical research company’s stock worth $1,617,000 after acquiring an additional 1,267 shares in the last quarter. Provident Investment Management Inc. boosted its position in Amgen by 1.4% during the 3rd quarter. Provident Investment Management Inc. now owns 4,670 shares of the medical research company’s stock worth $1,318,000 after acquiring an additional 65 shares during the period. Finally, Advisory Services Network LLC boosted its position in Amgen by 6.0% during the 3rd quarter. Advisory Services Network LLC now owns 33,551 shares of the medical research company’s stock worth $9,468,000 after acquiring an additional 1,903 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Morgan Stanley upped their target price on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Daiwa Securities Group boosted their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Cantor Fitzgerald upped their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Finally, Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $354.00.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Stock Down 1.4%

Shares of Amgen stock opened at $361.13 on Wednesday. The firm has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a P/E/G ratio of 3.63 and a beta of 0.45. The stock has a 50-day simple moving average of $359.26 and a 200-day simple moving average of $326.77. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.